{"type":"rich","version":"1.0","title":"The BioPharm Brief: Cell Therapy, Capacity, and Contracts","description":"The BioPharm Brief covers Resolution Therapeutics’ completed enrollment of RTX001 in the EMERALD trial, Samsung Biologics’ $262 million manufacturing deal, and CordenPharma’s $80 million investment to expand sterile injectable capacity.","author_name":"The BioPharm Brief","author_url":"https://audioboom.com/channels/5167274-the-biopharm-brief","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43834802/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":""}